$300 Million is the total value of Sarissa Capital Management LP's 8 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 45.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | Buy | BIOGEN INC | $104,163,000 | +22.9% | 383,858 | +23.8% | 34.77% | +3.8% |
| New | BIOVERATIV INC | $70,098,000 | – | 1,165,000 | +100.0% | 23.40% | – | |
| MDCO | MEDICINES CO | $66,593,000 | -22.3% | 1,752,000 | 0.0% | 22.23% | -34.3% | |
| INVA | Buy | INNOVIVA INC | $44,681,000 | -5.7% | 3,490,705 | +1.9% | 14.92% | -20.3% |
| NVLNF | NOVELION THERAPEUTICS INC | $9,460,000 | -14.1% | 1,025,000 | 0.0% | 3.16% | -27.4% | |
| ADXS | ADVAXIS INC | $2,201,000 | -20.6% | 339,180 | 0.0% | 0.74% | -32.9% | |
| APRI | APRICUS BIOSCIENCES INC | $1,636,000 | -46.4% | 1,447,906 | 0.0% | 0.55% | -54.8% | |
| ABBV | ABBVIE INC. | $725,000 | +11.4% | 10,000 | 0.0% | 0.24% | -5.8% | |
| AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -1,013,616 | -100.0% | -0.24% | – |
| VVUS | Exit | VIVUS INC | $0 | – | -2,573,943 | -100.0% | -1.14% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -360,000 | -100.0% | -2.31% | – |
| BIVV | Exit | BIOVERATIV INC | $0 | – | -155,000 | -100.0% | -3.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.